- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | Sunshine Biopharma, Inc - 8-K, Current Report | 3 | SEC Filings | ||
| Di | Bio-Path Holdings, Sunshine Biopharma, INVO Bioscience among healthcare movers | 3 | Seeking Alpha | ||
| Mo | SBFM, BPTH and INDO among pre-market losers | 4 | Seeking Alpha | ||
| 19.04. | Sunshine biopharma's Nora Pharma receives Health Canada approval for Niopeg | 4 | Seeking Alpha | ||
| 19.04. | Pre-market Movers: Zhongchao, Redwoods Acquisition Corp., Tritium DCFC, Nexalin Technology, Sunshine Biopharma | 323 | AFX News | CANBERA (dpa-AFX) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 08.05 A.M. ET).In the Green Zhongchao Inc. (ZCMD) is up over 96% at $2.83.
Redwoods... ► Artikel lesen | |
| 19.04. | Sunshine Biopharma, Inc.: Sunshine Biopharma's Nora Pharma Receives Health Canada Approval for Niopeg, a Biosimilar of Neulasta | 554 | ACCESSWIRE | NEW YORK, NY / ACCESSWIRE / April 19, 2024 / Sunshine Biopharma Inc. (NASDAQ:SBFM), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including... ► Artikel lesen | |
| 15.04. | How Is The Market Feeling About Sunshine Biopharma? | 2 | Benzinga.com | ||
| 12.04. | Sunshine Biopharma, Inc.: Sunshine Biopharma Announces Reverse Stock Split | 309 | ACCESSWIRE | NEW YORK, NY / ACCESSWIRE / April 12, 2024 / Sunshine Biopharma, Inc. (NASDAQ:SBFM) (the "Company" or "Sunshine Biopharma"), a pharmaceutical company offering and researching life-saving medicines in... ► Artikel lesen | |
| 01.04. | Sunshine Biopharma, Inc - 8-K, Current Report | 3 | SEC Filings | ||
| 01.04. | Sunshine Biopharma reports FY results | 2 | Seeking Alpha | ||
| 01.04. | Sunshine Biopharma, Inc.: Sunshine Biopharma Reports Operating Results for the Fiscal Year Ended December 31, 2023 | 286 | ACCESSWIRE | Sales Grew at an Average Rate of 14% Per Quarter During the YearNEW YORK, NY / ACCESSWIRE / April 1, 2024 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering and... ► Artikel lesen | |
| 28.03. | Sunshine Biopharma, Inc - 10-K, Annual Report | 3 | SEC Filings | ||
| 04.03. | Why Is Sunshine Biopharma (SBFM) Stock Down 17% Today? | 11 | InvestorPlace | ||
| 01.03. | Sunshine Biopharma, Inc - 8-K, Current Report | 3 | SEC Filings | ||
| 15.02. | Sunshine Biopharma completes $10M public offering | 3 | Investing.com | ||
| 15.02. | Sunshine Biopharma, Inc. Announces Closing of $10.0 Million Underwritten Public Offering | 322 | ACCESSWIRE | NEW YORK, NY / ACCESSWIRE / February 15, 2024 / Sunshine Biopharma, Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic... ► Artikel lesen | |
| 13.02. | Sunshine Biopharma sets $10 million public offering | 5 | Investing.com | ||
| 13.02. | Sunshine Biopharma, Inc. Announces Pricing of $10.0 Million Underwritten Public Offering | 272 | ACCESSWIRE | NEW YORK, NY / ACCESSWIRE / February 13, 2024 / Sunshine Biopharma, Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic... ► Artikel lesen | |
| 12.02. | Sunshine Biopharma, Inc - 8-K, Current Report | 4 | SEC Filings | ||
| 09.02. | Sunshine Biopharma, Inc - S-1/A, General form for registration of securities | - | SEC Filings |
Seite:
1 2 Weiter >>
35 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ASTRIA THERAPEUTICS | 9,000 | +7,14 % | Astria Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update | BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today reported... ► Artikel lesen | |
| ORAMED PHARMACEUTICALS | 2,141 | -7,28 % | Oramed Pharmaceuticals Inc.: Oramed Letter to Shareholders | Initiating Phase 3 oral insulin trial in the United States under a new protocol
JV with Chinese Partner, HTIT
Scilex Senior Secured Note
PeriTech Asset Purchase & Strategic Out-licensing
NEW... ► Artikel lesen | |
| CASSAVA SCIENCES | 20,540 | -1,53 % | Cassava Sciences, Inc.: Cassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 Trials | An Independent Data and Safety Monitoring Board (DSMB) Recently Evaluated the Interim Patient Safety Database for Oral Simufilam in On-going Phase 3 Trials. The DSMB Recommended Both Phase 3 Trials... ► Artikel lesen | |
| ROCKET LAB USA | 3,510 | -0,28 % | How Rocket Lab Outgrew Billionaire Elon Musk's Space Company in Q1 | ||
| LIPOCINE | 4,690 | +3,76 % | Lipocine Inc. - 8-K, Current Report | ||
| BOIRON | 34,150 | +1,49 % | BOIRON: Outlook 2023 - Communication calendar 2024 | The Board of Directors of Laboratoires BOIRON met on 19 December 2023, under the chairmanship of Mr Thierry Boiron.
At this meeting, the Board reviewed the latest business and earnings forecasts... ► Artikel lesen | |
| ALLERGY THERAPEUTICS | 0,030 | 0,00 % | XFRA HHU: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| MEDICINOVA | 1,250 | 0,00 % | MediciNova, Inc.: MediciNova Announces Abstract Regarding Results of a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the 2024 American Society of Clinical Oncology Annual Meeting (2024 ASCO) | LA JOLLA, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange... ► Artikel lesen | |
| ESSA PHARMA | 6,080 | -0,65 % | Essa Pharma Inc. Reports Results Of Annual General Meeting Of Shareholders | SOUTH SAN FRANCISCO, USA and VANCOUVER, CANADA, March 7, 2024 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ: EPIX), a clinical stage pharmaceutical company focused on developing... ► Artikel lesen | |
| AQUESTIVE THERAPEUTICS | 4,080 | +3,82 % | Aquestive wins FDA approval for anti-seizure therapy Libervant | ||
| HARROW | 10,530 | +5,30 % | Harrow Health, Inc. Announces Fourth Quarter and Year-End 2023 Financial Results | NASHVILLE, Tenn.--(BUSINESS WIRE)--Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, announced results for the fourth quarter and year ended December 31, 2023. The Company also... ► Artikel lesen | |
| CYANOTECH | 0,260 | 0,00 % | Delisting of Securities of NanoString Technologies, Inc.; Remark Holdings, Inc.; Sunworks, Inc.; Cyanotech Corporation; Sientra, Inc.; Charge Enterprises, Inc. and others from The Nasdaq Stock Market | NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- The Nasdaq Stock Market announced today that it will delist the common stock of NanoString Technologies, Inc. NanoString Technologies, Inc.'s securities... ► Artikel lesen | |
| SHINECO | 0,810 | +1,39 % | Shineco, Inc.: Shineco Regains Compliance with Nasdaq Minimum Bid Price Requirement | BEIJING, March 12, 2024 (GLOBE NEWSWIRE) -- Shineco, Inc. ("Shineco" or the "Company"; NASDAQ: SISI), a provider of technologically advanced healthcare products and services, announced today that... ► Artikel lesen | |
| CUMBERLAND PHARMACEUTICALS | 1,760 | +7,65 % | Cumberland Pharmaceuticals Inc.: Cumberland Pharmaceuticals Reports Annual 2023 Financial Results | 2023 highlights include expanded FDA approval and new study publications
NASHVILLE, Tenn., March 5, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical... ► Artikel lesen | |
| REVIVA PHARMACEUTICALS | 2,990 | +0,34 % | Reviva Pharmaceuticals: Reviva Announces FDA Alignment on Brilaroxazine Clinical Trials for NDA in Schizophrenia | - FDA acceptance of 4-week global registrational Phase 3 RECOVER-2 study - - Two positive 4-week studies plus a 12-month long-term safety study have potential to support a New Drug Application (NDA)... ► Artikel lesen |
Das Unternehmen SUNSHINE BIOPHARMA INC kann der Branche Pharma zugeordnet werden. Die relative Kursveränderung beträgt aktuell +17,66 % bei einem Aktienkurs von 0,950 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
